Human papillomavirus (HPV) genotyping by HPV DNA chip in cervical cancer and precancerous lesions

Abstract

ObjectivesThe human papillomavirus (HPV) is a well-known cause of cervical cancer. HPV tests are used as an adjunct test to decrease the false-negative rate of cytological screening. However, attempts are being made to replace the cytological screening with HPV tests. Therefore, this study was performed to examine the possibility of using HPV tests as screening test.Materials and methodsThe results of the tests that were performed at the same time including the ThinPrep cytology, the high-risk group hybrid capture II (HC-II) test, the HPV DNA chip (HD-C) test, and a punch biopsy were compared in 400 women who were referred to us due to abnormal cytology or cervicogram. The accuracy of each test was then evaluated, and the type of virus was investigated using a HD-C test.ResultsThe positive predictive values detected by the high-risk group HC-II test and HD-C test according to the histological diagnosis outcomes were 56.8 and 53.8%, respectively, for cervicitis; 91.5 and 91.5%, respectively, for cervical intraepithelial neoplasia I (CIN I); 88.1% and 81.0%, respectively, for CIN II; 88.6 and 84.2%, respectively, for CIN III, and 92.5 and 88.7%, respectively, for cancer (in 53 patients). The most prevalent types of HPV according to the HPV tests were types 16, 58, 18, and 52 in which type 16 was detected in the more advanced lesions. The sensitivity was 88.4% for the ThinPrep cytology, 89.9% for the HC-II for the high-risk group, and 86.2% for the HD-C test.ConclusionThese results suggest the possibility of using the HC-II and HD-C tests as screening tests, which have a similar sensitivity as the ThinPrep cytology. Nonetheless, randomized controlled trials will be needed before the actual application of the HPV tests as screening tests. Despite the fact that the importance of HPV type 16 in cancer development was confirmed, the prevalence of types 58 and 52 were relatively high compared with those found in other studies, showing a need for further studies on this subject. These HPV types need to be considered in vaccine development.

Comparison of Human Papillomavirus Detection and Typing by Hybrid Capture 2, Linear Array, DNA Chip, and Cycle Sequencing in Cervical Swab Samples

“…The specimens were denatured at 65-C for 45 minutes and hybridized under highstringency conditions with a mixture of RNA probes that detect 13 different carcinogenic HPV types: 16,18,31,33,35,39,45,51,52,56,58,59, and 68. The resultant DNA-RNA hybrids were captured on the surface of the microtiter plate wells coated with an antiYDNA-RNA hybrid antibody.…”

“…The HPV DNA Chip contains 22 type-specific probes that consist of 15 high-risk types (16,18,31,33,35,39,45, 51, 52, 56, 58, 59, 66, 68, and 69) and 7 low-risk types (6, 11, 34, 40, 42, 43, and 44). Procedures for HPV DNA typing with the HPV DNA chip were performed as described previously.…”

“…The concordance for the detection of HPV 16 and 18 between the DNA chip and cycle sequencing, and LA HPV and sequencing was 95%, showing substantial agreement (J coefficient = 0.90). The concordance for the detection of 15 high-risk HPVs (16,18,31,33,35,39,45, 51, 52, 56, 58, 59, 68, 73, and 82) between the DNA chip and sequencing was 85% with a J value of 0.61, whereas that for the detection of 15 high-risk HPVs between LA HPV and sequencing was 82.5% with a J value of 0.54 (Table 4).…”

The role of human papillomavirus typization and cytology in early detection of relapse of cervical intraepithelial neoplasia

“…11 koristeći hybrid capture II test (HC II) dokazali su skoro identičnu vrednost senzitivnosti tipizacije HPV i citologije. Senzitivnost tipizacije iznosila je 89,9%, a citologije 86,2%.…”

“…U istom radu prilikom određivanja vrste (genotipa) virusa i njihove udruženosti sa neoplazijama višeg gradusa, sem visokog procenta HPV 16 i 18 utvrdili su i veliki procenat virusa tipa 52 i 58. Iz tih razloga, ovi autori naglašavaju da bi se i ove vrste virusa možda mogle uključiti u HPV vakcinaciju 11 .…”